Mary T Szela
CIK 1410289 · CEO and President · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$24.22M
Companies
12
Total Filings
80
Lifetime Open-Market Net
-$7.54M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABSI | Director | 21,300 | $7.13 | $151.9K | $148.9K | 4 | 2026-07-06 |
| TLSI | CEO and President | 1,077,683 | $4.33 | $4.67M | $0 | 1 | 2026-07-01 |
| KURA | Director | — | $9.31 | — | $0 | 9 | 2026-06-04 |
| TLSIW | CEO and President | 1,065,215 | $0.88 | $937.4K | $350.7K | 10 | 2026-05-18 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 3 | 2024-06-21 |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Director | 0 | $199.92 | $0 | $0 | 4 | 2023-06-16 |
| CHRS | Director | 0 | $1.44 | $0 | -$966.8K | 9 | 2021-01-13 |
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | — | $5.54 | — | $0 | 3 | 2020-06-22 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Chief Executive Officer | 4,384 | — | — | $0 | 2 | 2017-05-11 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Chief Executive Officer | — | — | — | $0 | 3 | 2016-11-30 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 3 | 2015-08-27 |
| ABT | Senior Vice President | 172,123 | $107.27 | $18.46M | -$7.07M | 27 | 2011-12-16 |
Recent Filings · Page 2 of 8
80 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-06 | KURA | Grant (A) | — | $0 | EDGAR |
| 2025-02-19 | TLSIW | Grant (A) | +21,089 | $0 | EDGAR |
| 2025-01-31 | TLSIW | Buy (P) | +10,040 | $51.8K | EDGAR |
| 2025-01-29 | TLSIW | Mixed | +49,542 | $50.3K | EDGAR |
| 2024-09-13 | TLSIW | Buy (P) | +14,815 | $75.4K | EDGAR |
| 2024-09-12 | TLSIW | Buy (P) | +5,000 | $24.9K | EDGAR |
| 2024-06-21 | Omega Therapeutics, Inc. (OMGA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | KURA | Grant (A) | — | $0 | EDGAR |
| 2024-02-14 | TLSIW | Grant (A) | +84,899 | $0 | EDGAR |
| 2023-08-15 | — | Grant (A) | — | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.